21 CFR 1271: A Practitioner's Guide

If you practice regenerative medicine in the United States, 21 CFR Part 1271 applies to you. It is the federal regulation that governs human cells, tissues, and cellular and tissue-based products (HCT/Ps). Understanding it is not optional. It is the difference between practicing with a defensible regulatory position and practicing on borrowed time.

This guide covers what 21 CFR 1271 regulates, the two regulatory pathways (Section 361 and Section 351), donor screening requirements, record retention, and what you can and cannot claim in marketing materials. It is written for practicing clinicians, not lawyers. It is accurate to the best of our knowledge as of August 2026, but regulations change. Always verify against the current FDA guidance for your specific situation.

What Is 21 CFR 1271?

21 CFR Part 1271 is the FDA's regulation for "Human Cells, Tissues, and Cellular and Tissue-Based Products" (HCT/Ps). It was issued under the authority of Section 361 of the Public Health Service Act (PHS Act), which gives the FDA the power to prevent the introduction, transmission, or spread of communicable diseases.

The regulation covers:

• Tissue donation and screening (who can donate, what diseases are screened)
• Establishment registration (facilities that handle HCT/Ps must register with the FDA)
• Donor eligibility (screening and testing requirements for donors)
• Current Good Tissue Practice (cGTP) (processing, labeling, storage, and distribution standards)
• Recordkeeping (what records you must keep and for how long)
• Adverse event reporting (what to do when something goes wrong)

What it does not cover: therapeutic efficacy, clinical outcomes, or whether the product "works." 21 CFR 1271 is about safety and communication, not effectiveness. A product can fully comply with 1271 and still not be FDA-approved for any therapeutic use. This distinction is the single most misunderstood concept in regenerative medicine.

Section 361 vs Section 351: The Two Pathways

HCT/Ps are regulated under one of two pathways, depending on how they meet the criteria in 21 CFR 1271.10(a):

Criterion	Section 361 (Lower Risk)	Section 351 (Higher Risk)
Minimally manipulated	Yes	May be more than minimally manipulated
Same surgical procedure	Same person, same procedure, same establishment	May involve different person or establishment
Homologous use	Performs the same function in the recipient as in the donor	May perform a different function
No systemic effect	Does not achieve its primary effect through systemic metabolism	May have systemic metabolic effects

If all four criteria are met: the HCT/P is regulated solely under Section 361. No premarket approval is required. The product must still comply with donor screening, cGTP, and recordkeeping requirements.

If any criterion is not met: the HCT/P is regulated under Section 351 (the Federal Food, Drug, and Cosmetic Act). This requires premarket approval (a Biologics License Application, or BLA), which is a multi-year, multi-million-dollar process. Most regenerative medicine products on the market are not Section 351-approved. They are either Section 361-compliant or operating in a regulatory gray zone.

Donor Screening Requirements

Under 21 CFR 1271.75, donors of HCT/Ps must be screened for risk factors and tested for communicable diseases. The screening includes:

Donor Eligibility Determination

• Review of medical history for risk factors (high-risk behaviors, travel history, recent tattoos, etc.)
• Physical examination for signs of communicable disease
• Testing for relevant communicable diseases (HIV 1 and 2, hepatitis B, hepatitis C, syphilis, and others depending on the tissue type)
• Review of donor records by a responsible person at the tissue establishment

What You Should Ask Your Supplier

• What is your donor screening protocol?
• Which diseases do you test for?
• What is the donor age range? (21 CFR 1271.65 sets age limits for certain tissues)
• Do you maintain donor eligibility records?
• Can you provide documentation for the specific donor whose tissue was used for my batch?

If the supplier cannot answer these questions, they may not be following 1271.75. That is a regulatory and safety risk.

Record Retention: What You Must Keep and for How Long

21 CFR 1271.190 requires that tissue establishments maintain records for a minimum period. The requirement:

• Records of donor eligibility: minimum 10 years after the date of the HCT/P administration
• Processing records: minimum 10 years
• Distribution records: minimum 10 years (so you can trace where each lot went)
• Adverse event reports: as specified in 1271.350

What You Can and Cannot Claim

The FDA and FTC have specific rules about what you can say about HCT/Ps in marketing materials:

You can say	You cannot say
"Exosome material derived from [source]"	"Exosomes treat [disease]"
"Wharton's jelly-derived MSC exosomes"	"Stem cell therapy for [condition]"
"Research use only material"	"FDA-approved exosome treatment"
"Independent Eurofins COA included"	"Clinically proven to reduce inflammation"
"Documentation available on request"	"Clinically proven to promote healing"

The distinction is between characterization (describing what the material is) and therapeutic claims (describing what the material does). Characterization is factual. Therapeutic claims require FDA approval. Most regenerative medicine marketing violations come from crossing this line.

The FTC Standard

For advertising claims, the FTC applies the standard of "competent and reliable scientific evidence." This means:

• Studies must be properly designed and conducted
• Results must be substantiated by the type and quality of evidence the claim implies
• Patient testimonials alone are not sufficient
• Practitioner clinical experience alone is not sufficient

If you say "studies show exosomes reduce inflammation," you need studies. If you say "my patients report reduced inflammation," you need to be very careful that the claim does not imply clinical evidence that you do not have.

The Same Surgical Procedure Exception

21 CFR 1271.15(b) contains the "same surgical procedure" exception. Under this exception, if the HCT/P is:

1. Removed from and implanted into the same patient
2. In the same surgical procedure
3. At the same establishment

then the 1271 requirements do not apply. This is the regulatory basis for PRP (platelet-rich plasma) and bone marrow aspirate procedures where the patient's own tissue is processed and re-implanted in one visit.

State Regulations Layer On Top

21 CFR 1271 is the federal floor, not the ceiling. Many states have additional regulations that apply to regenerative medicine:

• Scope of practice laws (who can perform which procedures, e.g., MD vs NP vs RN)
• Stem cell clinic laws (some states restrict or ban certain stem cell procedures)
• Practice act regulations (state medical boards may have specific rules for regenerative medicine)
• Advertising restrictions (state medical boards may prohibit certain marketing claims)

Check our state-by-state regulatory map for your state. But do not rely solely on the map. State laws change. Verify with your state medical board and your malpractice carrier.

Practical Steps for Your Practice

1. Register your establishment with the FDA if you process or store HCT/Ps (21 CFR 1271.21)
2. Implement donor screening protocols that comply with 1271.75
3. Maintain records for 10+ years from the date of administration
4. Audit your marketing materials for therapeutic claims. Replace "treats" with "may be associated with" or remove the claim entirely.
5. Request and file COAs from every supplier for every batch
6. Train your staff on what they can and cannot say to patients about regenerative products
7. Know your state laws in addition to the federal framework

The Bottom Line

21 CFR 1271 is not complicated, but it is detailed. The four criteria in 1271.10(a) determine whether a product is Section 361 (no premarket approval) or Section 351 (premarket approval required). Donor screening, recordkeeping, and claim restrictions apply regardless of which pathway applies. The same surgical procedure exception is narrow and does not cover most regenerative medicine products.

The clinicians who get into regulatory trouble are not the ones who understand the framework and apply it. They are the ones who assume the framework does not apply to them, or who rely on their supplier's assurance that "everything is compliant" without verifying what that means.

Verify. Document. Retain. If you cannot verify it, do not claim it. If you cannot document it, do not do it. If you cannot retain the records, start a system that can.